Request that the FDA determine whether BACTROBAN® (mupirocin calcium) Nasal Ointment, 2%, approved under NDA 050703 (held by GlaxoSmithKline), has been discontinued from sale for safety or efficacy reasons
🏛 Food and Drug Administration (FDA)FDA-2020-P-1617
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.